<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230892</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00027953</org_study_id>
    <secondary_id>Emory #00000681</secondary_id>
    <nct_id>NCT01230892</nct_id>
  </id_info>
  <brief_title>Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques</brief_title>
  <official_title>The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Georgia Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nebivolol is a novel blood pressure lowering drug with an additional effect on the inner&#xD;
      lining of blood vessels to release a compound called nitric oxide that can relax blood&#xD;
      vessels. Atenolol is a blood pressure reducing agent without the ability to release nitric&#xD;
      oxide and effect additional blood vessel relaxation.&#xD;
&#xD;
      The goal of this proposal is to compare Nebivolol and Atenolol with respect to the following&#xD;
      parameters:&#xD;
&#xD;
        -  Plaque within arteries supplying the heart in terms of its volume and composition as&#xD;
           assessed by ultrasound within these arteries.&#xD;
&#xD;
        -  Ability of small arteries in the heart to open up and deliver an enhanced blood supply&#xD;
           in response to drug called Adenosine (routinely used in the cardiac catheterization&#xD;
           laboratory) as assessed by pressure and flow detecting catheters within these arteries.&#xD;
&#xD;
        -  Ability of the inner lining of arteries that supply the heart to release a relaxing&#xD;
           compound called nitric oxide in response to injection of Acetylcholine (also used in the&#xD;
           cardiac catheterization laboratory) as assessed by squirting dye into these arteries&#xD;
&#xD;
        -  Local forces that affect blood flow in the arteries supplying the heart as assessed by&#xD;
           superimposing the above data into complex maps created offline at Georgia Institute of&#xD;
           Technology.&#xD;
&#xD;
      It is likely that Nebivolol causes the plaque within arteries supplying the heart to change&#xD;
      from the 'vulnerable' type to the 'stable' type plaque. There are several features of&#xD;
      &quot;vulnerable plaques&quot; that can be detected in arteries of the heart using intravascular&#xD;
      ultrasound (a small ultrasound camera that goes in the arteries of the heart). The&#xD;
      investigators hypothesis is that Nebivolol will prove superior to Atenolol in reducing&#xD;
      'vulnerable plaques', improve blood flow within the small arteries and the health of inner&#xD;
      lining of these arteries at the 1 year time point. The investigators plan to enroll 20&#xD;
      patients into the study (26 patient including dropouts) who will be randomized in a 1:1&#xD;
      manner to Nebivolol Vs Atenolol for 1 year and repeat evaluation at that time point.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hypothesis:&#xD;
&#xD;
      Nebivolol therapy will reduce the number of thin-cap fibroatheromas, VH-IVUS defined&#xD;
      &quot;vulnerable plaques&quot; compared to Atenolol in patients undergoing serial angiography and IVUS.&#xD;
&#xD;
      Secondary Hypotheses:&#xD;
&#xD;
        -  Nebivolol therapy will improve coronary microvascular function&#xD;
&#xD;
        -  Nebivolol therapy will improve coronary endothelial function&#xD;
&#xD;
        -  Nebivolol therapy will improve coronary wall shear stress&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
      To evaluate, in patients with stable angina or acute coronary syndromes and moderate&#xD;
      angiographic coronary artery disease, the effects of Nebivolol 5 mg a day compared to&#xD;
      Atenolol 50 mg a day on:&#xD;
&#xD;
        -  The number of thin cap fibroatheromas, percent necrotic core, and percent atheroma&#xD;
           volume as defined by the novel Virtual Histology IVUS (VHâ„¢ IVUS).&#xD;
&#xD;
        -  The coronary shear stress profile measured using 3 dimensional vessel reconstruction,&#xD;
           flow velocity measurements, and computational fluid dynamics.&#xD;
&#xD;
        -  Microvascular function as determined by coronary flow reserve and fractional flow&#xD;
           reserve measured by invasive Doppler/pressure assessment.&#xD;
&#xD;
        -  Endothelial function as determined by the response of quantitative coronary angiography&#xD;
           and Doppler assessment to intracoronary acetylcholine challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS</measure>
    <time_frame>1 year</time_frame>
    <description>Presence of thin-cap fibroatheroma as defined by virtual histology-intravascular ultrasound (VH-IVUS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>10 mg PO qday</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>100 mg PO qday</description>
    <arm_group_label>Atenolol</arm_group_label>
    <other_name>Senormin</other_name>
    <other_name>Tenormin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stable angina or acute coronary syndrome&#xD;
&#xD;
          -  Moderate coronary lesion (defined as a lesion significant enough by the treating&#xD;
             physician to warrant further evaluation using CFR or FFR or intravascular ultrasound&#xD;
             assessment).&#xD;
&#xD;
          -  Lesion located in the proximal 60mm of the RCA or LAD.&#xD;
&#xD;
          -  On stable medical therapy for other cardiac risk factors.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left Main lesion greater than 50% stenosis&#xD;
&#xD;
          -  Patients with a history of coronary artery bypass surgery&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  Patients presenting with a STEMI.&#xD;
&#xD;
          -  Inability to provide informed consent prior to randomization&#xD;
&#xD;
          -  Creatinine &gt;1.5&#xD;
&#xD;
          -  Lesions located beyond 60mm in an epicardial vessel&#xD;
&#xD;
          -  Coronary anatomy requiring CABG&#xD;
&#xD;
          -  B-blocker, calcium channel blocker or extended-release nitrate therapy within last 48&#xD;
             hours.&#xD;
&#xD;
          -  Bradycardia (HR&lt;50 bpm)&#xD;
&#xD;
          -  Hypotension (SBP&lt;100mmHg)&#xD;
&#xD;
          -  Severe COPD by pulmonary function testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Habib Samady, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>September 10, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <results_first_submitted>February 12, 2015</results_first_submitted>
  <results_first_submitted_qc>February 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2015</results_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Habib Samady</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol</title>
          <description>Nebivolol: 10 mg PO qday</description>
        </group>
        <group group_id="P2">
          <title>Atenolol</title>
          <description>Atenolol: 100 mg PO qday</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>4 subjects either withdrew or were lost to follow-up and not included in analysis population. Additionally, one subject in the Atenolol arm was removed from analysis population due to IVUS occurring in the incorrect artery.</population>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>Nebivolol: 10 mg PO qday</description>
        </group>
        <group group_id="B2">
          <title>Atenolol</title>
          <description>Atenolol: 100 mg PO qday</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="10"/>
                    <measurement group_id="B2" value="50" spread="11"/>
                    <measurement group_id="B3" value="52" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS</title>
        <description>Presence of thin-cap fibroatheroma as defined by virtual histology-intravascular ultrasound (VH-IVUS)</description>
        <time_frame>1 year</time_frame>
        <population>4 subjects either withdrew or were lost to follow-up and not included in analysis population. Additionally, one subject in the Atenolol arm was removed from analysis population due to IVUS occurring in the incorrect artery and one subject in the Nebivolol arm was removed due to the IVUS catheter malfunctioning.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: 10 mg PO qday</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Atenolol: 100 mg PO qday</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS</title>
          <description>Presence of thin-cap fibroatheroma as defined by virtual histology-intravascular ultrasound (VH-IVUS)</description>
          <population>4 subjects either withdrew or were lost to follow-up and not included in analysis population. Additionally, one subject in the Atenolol arm was removed from analysis population due to IVUS occurring in the incorrect artery and one subject in the Nebivolol arm was removed due to the IVUS catheter malfunctioning.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol</title>
          <description>Nebivolol: 10 mg PO qday</description>
        </group>
        <group group_id="E2">
          <title>Atenolol</title>
          <description>Atenolol: 100 mg PO qday</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Habib Samady</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-5299</phone>
      <email>hsamady@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

